CareDx reported Q4 FY2025 revenue of USD 108 million, up 25% year-over-year, including testing services revenue of USD 78 million (up 23%) on testing volume of about 53,000 (up 17%). Patient and digital solutions revenue was USD 16.8 million (up 47%) and product revenue was USD 13.3 million (up 17%). Q4 average revenue per test was about USD 1,480, including about USD 5 million in prior period revenue. CareDx posted a Q4 GAAP net loss of USD 4 million and adjusted EBITDA of USD 7 million, with cash flow from operations of USD 21.4 million; it repurchased USD 12 million of shares (773,000 shares at an average price of USD 15.79). For FY2025, CareDx reported revenue of USD 380 million (up 14%), including testing services revenue of USD 275 million (up 10%) on testing volume of about 200,000 (up 14%), patient and digital solutions revenue of USD 57 million (up 31%), and product revenue of USD 48 million (up 19%). FY2025 GAAP net loss was USD 21 million, non-GAAP net income was USD 32 million, adjusted EBITDA was USD 32 million, and cash flow from operations was USD 42 million; cash, cash equivalents and marketable securities were about USD 200 million at year-end. The company repurchased USD 88 million of shares in FY2025 (5.8 million shares at an average price of USD 15.16). Business updates included publication of a third SHORE registry manuscript supporting HeartCare, progress on Epic Aura integrations with seven transplant centers live and about 20 implementations underway, the launch of ImmuneScape via a collaboration with 10x Genomics, and pivotal validation data for AlloHeme as CareDx expands beyond solid organ transplantation into cell therapy and hematologic malignancies. For FY2026, CareDx guided for revenue of USD 420 million to USD 444 million, including an estimated 6-month Medicare LCD impact of about USD 7.5 million, and adjusted EBITDA of USD 30 million to USD 45 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260224132013) on February 24, 2026, and is solely responsible for the information contained therein.